文
论文分享
演练场
杂货铺
论文推荐
字
编辑器下载
登录
注册
Phase 3 trial results for rolapitant, a novel NK-1 receptor antagonist, in the prevention of chemotherapy-induced nausea and vomiting (CINV) in subjects receiving moderately emetogenic chemotherapy (MEC).
复制论文ID
分享
摘要
作者
参考文献
暂无分享,去
创建一个
R. Martell
|
L. Schwartzberg
|
M. Hedley
|
M. Modiano
|
A. Poma
|
I. Schnadig
保存到论文桶